TECHNE CORPORATION
HomeCompany NewsFinancial InformationAbout TechneMap - DirectionsProductsContact Us

Segment Results - 3rd Quarter Fiscal Year 2008

TECHNE CORPORATION AND SUBSIDIARIES
(in thousands of $’s, except per share data)

  Fiscal 2008 Increase(Decrease) From Fiscal 2007
First Quarter Second Quarter Third Qurter YTD Percent Of Sales First Quarter Second Quarter Third Qurter YTD
Sales 57,987 62,142 69,522 189,651 100% 5,636 9,633 9,325 24,594
Cost of sales 12,104 12,751 14,146 39,001 21% 867 2,037 2,127 5,031
Gross margin 45,883 49,391 55,376 150,650 79% 4,769 7,596 7,198 19,563
                   
Gross margin percentage 79.1% 79.5% 79.7% 79.4%          
                   
SG&A expense 8,090 10,645 8,994 27,729 15% 1,023 1,815 1,765 4,603
R&D expense 5,181 5,562 5,839 16,582 9% 326 518 670 1,514
Amortization expense 288 282 283 853 - (115) (122) (120) (357)
Interest expense 0 0 0 0 - (268) (815) 0 (1,083)
Interest income (2,998) (3,252) (3,155) (9,405) (5%) (1,322) (1,296) (918) (3,536)
Other non-operating ex., net 569 573 423 1,565 - 84 145 (344) (115)
  11,130 13,810 12,384 37,324 19% (272) 245 1,053 1,026
Earnings before income taxes 34,753 35,581 42,992 113,326 60% 5,041 7,351 6,145 18,537
Income taxes 11,681 11,942 13,402 37,025 20% 1,600 2,375 448 4,423
  23,072 23,639 29,590   76,301  40% 3,441 4,976 5,697 14,114
                   
Diluted earnings per share .58 .60 .76 1.94          
Weighted average diluted shares outstanding   39,587   39,497   39,108   39,396          

Back to Top
HEMATOLOGY DIVISION
(in thousands of $’s)

  Fiscal 2008 Increase(Decrease) From Fiscal 2007
First Quarter Second Quarter Third Qurter YTD Percent Of Sales First Quarter Second Quarter Third Qurter YTD
Sales 3,657 3,972 4,206 11,835 100% 155 146 542 843
Cost of sales 2,261 2,276 2,466 7,003 59% 163 129 381 673
Gross margin 1,396 1,696 1,740 4,832 41% (8) 17 161 170
                   
Gross margin percentage 38.2% 42.7% 41.4% 40.8%          
                   
SG&A expense 467 487 489 1,443 12% 69 48 58 175
R&D expense 179 194 199 572 5% (1) 4 1 4
Interest, net (120) (125) (123) (368) (3%) (39) (30) (12) (81)
  526 556 565 1,647 14% 29 22 47 98
Pretax result   870 1,140 1,175 3,185 27% (37)  (5) 114   72

Back to Top
BIOTECHNOLOGY DIVISION (1)
(in thousands of $’s)

  Fiscal 2008 Increase(Decrease) From Fiscal 2007
First Quarter Second Quarter Third Qurter YTD Percent Of Sales First Quarter Second Quarter Third Qurter YTD
Sales 45,328 46,576 52,912 144,816 100% 3,707 6,503 6,710 16,920
Intersegment sales (6,447) (7,433) (7,822) (21,702)   (748) (786) (750) (2,284)
  38,881 39,143 45,090 123,114   2,959 5,717 5,960 14,636
                   
Cost of sales 8,997 9,612 10,709 29,318 20% 515 1,929 1,668 4,112
Intersegment sales (6,174) (7,430) (7,755) (21,359)   (650) (995) (608) (2,253)
  2,823 2,182 2,954 7,959   (135) 934 1,060 1,859
                   
Gross margin 36,058 36,961 42,136 115,155 80% 3,094 4,783 4,900 12,777
                   
Gross margin percentage 80.2% 79.4% 79.8% 79.8%          
                   
SG&A expense 4,624 5,534 5,257 15,415 11% 611 870 1,091 2,572
R&D expense 5,002 5,368 5,640 16,010 11% 327 514 669 1,510
Amortization expense 288 282 283 853 1% (115) (122) (120) (357)
Interest, net (1,257) (1,309) (1,285) (3,851) (3%) (662) (587) (444) (1,693)
Exchange loss/(gain) 34 12 (5) 41 -- 34 12 (5) 41
  8,691 9,887 9,890 28,468 20% 195 687 1,191 2,073
Pretax result 27,367 27,074 32,246 86,687 60% 2,899 4,096 3,709 10,704

(1) Includes R&D Systems' Biotechnology Division, Fortron Bio Science, Inc., and BiosPacific, Inc.

Back to Top
R&D SYSTEMS EUROPE
(in thousands of £'s) 

  Fiscal 2008 Increase(Decrease) From Fiscal 2007
First Quarter Second Quarter Third Qurter YTD Percent Of Sales First Quarter Second Quarter Third Qurter YTD
Sales 7,605 9,301 10,180 27,086 100% 735 1,450 1,326 3,511
Cost of sales 3,455 4,053 4,392 11,900 44% 170 287 301 758
Gross margin 4,150 5,248 5,788 15,186 56% 565 1,163 1,025 2,753
                   
Gross margin percentage 54.6% 56.4% 56.9% 56.1%          
                   
SG&A expense 1,114 1,276 1,163 3,553 13% 40 40 88 168
Interest income (683) (773) (762) (2,218) (8%) (273) (293) (220) (786)
Exchange loss/(gain) (96) (81) (230) (407)  (2%) (174) (17) (252) (443)
  335 422 171 928 3% (407) (270) (384) (1,061)
Pretax result 3,815 4,826 5,617 14,258 53%   972 1,433 1,409   3,814

Back to Top
R&D SYSTEMS EUROPE
(in thousands of $’s)

  Fiscal 2008 Increase(Decrease) From Fiscal 2007
First Quarter Second Quarter Third Qurter YTD Percent Of Sales First Quarter Second Quarter Third Qurter YTD
Sales 15,449 19,027 20,226 54,702 100% 2,522 3,770 2,823 9,115
Cost of sales 7,020 8,293 8,726 24,039 44% 839 974 686 2,499
Gross margin 8,429 10,734 11,500 30,663 56% 1,683 2,796 2,137 6,616
                   
Gross margin percentage 54.6% 56.4% 56.9% 56.1%          
                   
SG&A expense 2,262 2,599 2,311 7,172 13% 242 194 199 635
Interest income (1,387) (1,576) (1,514) (4,477) (8%) (616) (643) (447) (1,706)
Exchange loss (198) (165) (457) (820) (2%) (345) (39) (499) (883)
  677 858 340 1,875 3% (719) (488) (747) (1,954)
Pretax result 7,752  9,876 11,160 28,788 53% 2,402 3,284 2,884 8,570

Back to Top
CORPORATE AND OTHER (2)
(in thousands of $’s)

  Fiscal 2008 Increase(Decrease) From Fiscal 2007
First Quarter Second Quarter Third Qurter YTD First Quarter Second Quarter Third Qurter YTD

Interest income

 234 242 233 709 5 36 15 56

Rental income

 67 111 91 269 (232) (130) 36 (326)

301 353 324 978 (227) (94) 51 (270)

               

SG&A expense

 737 2,025 937 3,699 101 703 417 1,221
Interest expense -- -- -- -- (268) (815) -- (1,083)

Other-Building expenses

 544 600 633 1,777 34 51 114 199

Other-Equity Investment losses

 256 237 343 836 129 (9) 82 202

1,537 2,862 1,913 6,312 (4) (70) 613 539

Pretax result

 (1,236) (2,509) (1,589) (5,334) (223)   (24) (562) (809)

Back to Top

(2) Unallocated corporate expenses and Techne’s share of losses by Hemerus Medical, LLC and Nephromics, LLC.